Previous 10 | Next 10 |
home / stock / zldpf / zldpf news
Takeda Receives FDA Approval for Brigatinib Takeda Pharmaceutical Company Limited ( TAK ) announced that the FDA has given a green signal for its ALUNBRIG (Brigatinib) in adult patients suffering from anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer. The lab...
Zealand Pharma A/S (ZEAL) Q1 2020 Earnings Conference Call May 14, 2020 10:00 AM ET Company Participants Lani Morvan – Investor Relations and Communication Emmanuel Dulac – President and Chief Executive Officer Matt Dallas – Senior Vice President and Chief Fi...
Zealand Pharma A/S (ZEAL) Q4 2019 Earnings Conference Call March 12, 2020 11:00 AM ET Company Participants Lani Morvan - Investor Relations Emmanuel Dulac - Chief Executive Officer Adam Steensberg - Chief Medical & Development Officer Conference Call Participants Thomas...
Press release - No. 23 / 2018 Zealand Pharma to attend Jefferies and Bryan, Garnier & Co Healthcare Conferences Copenhagen, November 12, 2018 - Britt Meelby Jensen, President and Chief Executive Officer of Zealand Pharma, will attend the Jefferies Healthcare Conference hel...
Press Release - No. 22 / 2018 Zealand hosts conference call on November 15 at 4 pm CET (10 am EST) to present third quarter results for 2018 Copenhagen, November 8, 2018 - Zealand Pharma A/S ("Zealand") (CVR no. 20 04 50 78) announces that it will be hosting a conf...
Press release - No. 21/2018 Zealand Pharma enrolls first patient in Phase 3 trial with glepaglutide for the treatment of short bowel syndrome The Phase 3 registration trial has enrolled th...
Press release - No. 20 / 2018 Zealand Pharma expands leadership team and appoints Marino Garcia as Senior Vice President of Corporate & Business Development Copenhagen, Denmark, October 1, 2018 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL), a Copenhagen-based biotechnology comp...
Company announcement - No. 24 / 2018 Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children The pediatric Phase 3 trial will enroll up to 40 children with Type 1 diabetes and evaluate time to recovery from insulin-i...
Company announcement - No. 23/2018 Zealand Pharma achieves primary and key secondary endpoints in pivotal Phase 3 trial with dasiglucagon for severe hypoglycemia All primary and key sec...
Company announcement - No. 22 / 2018 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, September 14, 2018 - Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and d...
News, Short Squeeze, Breakout and More Instantly...
Zealand Pharma A/S Ord Company Name:
ZLDPF Stock Symbol:
OTCMKTS Market:
Zealand Pharma A/S Ord Website:
Company announcement – No. 35 / 2024 Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE U...
Company announcement – No. 34 / 2024 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO T...
Company announcement – No. 33 / 2024 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CAN...